Brian D. Crandall brian.cr
Cornell University, Ithaca, NY B.S., Business and Hospitality, 2002
Johns Hopkins University, Baltimore, MD B.S., University and Departmental Honors, Biomedical Engineering, 2001
Duke University, Durham, NC B.S., Cum Laude, Economics, 2006
An opportunity to apply my business development and sales experience to a corporate strategy or private equity health care position.
McKesson Corporation, San Francisco, CA Manager, Corporate Strategy and Business Development, Summer 2010 Analyzed financial impact of health reform bill, identified an accountable care market opportunity and devel- oped a tiered strategy to build and bundle technology assets with patient solution services. Recommended short- term creation and marketing of a mobile application for drug adherence and patient data collection. Presented recommendations to three chief exec- utives and senior strategy council.
Ambrose Group, New York, NY Vice President, Sales and Business Development, 2007-2009
Developed $8.5M proprietary sales pipeline for a health, benefits, and human resource services company; facilitated client focus in the private equity, venture capital, and invest- ment management segments. Managed bank relationships, includ- ing UBS and Goldman Sachs; doubled spin-out deal flow. Youngest VP ever hired to the firm.
Cerner Corporation, New York, NY Manager, Business Development, 2005-2007
Built a secondary market that expanded beyond pharmaceuticals into the clinical space; entrepreneurial expansion resulted in the $17M acquisition of drug safety company Galt Associates by Cerner in October 2006. Led 9-month post-acquisition integration of the business develop- ment function.
An opportunity with a high-quality team in the biopharmaceutical industry.
Millennium Pharmaceuticals, Cambridge, MA
MBA Summer Intern, Corporate Strategy, Summer 2010
Supported Corporate Strategy team in the assessment of high-priority M&A candidates. Implemented efforts to benchmark leaders in oncology; results informed portfolio decision-making and BD processes.
SmartAnalyst, New York, NY Finance and Health Care Analyst, 2007-2009
Successfully lead analyst teams in India on a variety of biopharmaceutical research/consulting projects including: valuations/revenue forecasts of pipeline compounds, due diligence of potential in-licensing deals, quantita- tive evaluations of product portfolios and market strategy/research for pre-launch/launched products. Conducted hundreds of primary research interviews with KOLs across a variety of specialties.
Montgomery and Co. LLC, San Francisco, CA
Senior Analyst, Health Care Investment Banking, 2004-2005
Supported senior bankers in preparing marketing presentations and analytics
Credit Suisse, New York, NY Analyst, High Yield Structured Finance, 2001-2003
Supported senior bankers in originat- ing, structuring and underwriting collateralized debt obligations (CDOs) in leveraged loan and high yield bond asset classes. Assumed sole responsibil- ity for Analyst/Associate level work in execution of Stone Tower CLO, a landmark structured finance deal.
An opportunity to invest in and help operate innovative health care companies.
The Walt Disney Company, Glendale, CA Intern, Strategy & Business Development, Summer 2010
Assessed strategic fit and value of potential acquisition targets for Disney’s consumer products business unit. Constructed revenue forecast model to estimate the impact of The Disney Store’s retail expansion in China to Disney’s existing licensing business.
Citi Institutional Clients Group, San Francisco, CA and New York, NY Analyst, Corporate & Investment Banking, 2006-2009
Executed numerous multi-million debt transactions for health care, consumer, and technology companies by conducting extensive business and financial due diligence, and coordinat- ing interaction among institutional client, legal and deal team. Analyzed companies’ performance and built financial models to help clients meet financing needs for internal growth, mergers and acquisitions, and debt refinancings. Created pitch materials to advise clients on capital markets products and financial strategies such as restructurings.
| Page 2
| Page 3
| Page 4
| Page 5
| Page 6
| Page 7
| Page 8
| Page 9
| Page 10
| Page 11
| Page 12
| Page 13
| Page 14
| Page 15
| Page 16
| Page 17
| Page 18
| Page 19
| Page 20
| Page 21
| Page 22
| Page 23
| Page 24
| Page 25
| Page 26
| Page 27
| Page 28
| Page 29
| Page 30
| Page 31
| Page 32
| Page 33
| Page 34
| Page 35
| Page 36
| Page 37
| Page 38
| Page 39
| Page 40